Skip to content

Vaxcyte, Inc. PCVX Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Moderna logo
ModernaMRNA
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s accrued liabilities, current?
Vaxcyte, Inc. (PCVX) reported accrued liabilities, current of $30.25M in Q1 2026.
How has Vaxcyte, Inc.'s accrued liabilities, current changed year-over-year?
Vaxcyte, Inc.'s accrued liabilities, current increased by 16.1% year-over-year, from $26.04M to $30.25M.
What is the long-term trend for Vaxcyte, Inc.'s accrued liabilities, current?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s accrued liabilities, current has grown at a 52.5% compound annual growth rate (CAGR), from $3.77M to $31.07M.